
KalVista’s EKTERLY® Approved by FDA as First Oral On-Demand HAE Treatment
FDA Approves KalVista’s EKTERLY® as First Oral On-Demand Treatment for Hereditary Angioedema KalVista Pharmaceuticals, Inc. has announced a landmark development in the treatment of hereditary angioedema (HAE): the U.S. Food and Drug Administration (FDA) has officially approved EKTERLY® (sebetralstat), the…














